News | News By Subject | News by Disease News By Date | Search News

Graft vs. Host Disease News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
AbbVie (ABBV) Nabs Breakthrough Tag for Ibrutinib to Treat Chronic Graft-Versus-Host-Disease     6/29/2016
FDA Bestows Incyte (INCY)'s Ruxolitinib with Breakthrough Tag for Graft-Versus-Host Disease     6/23/2016
Chimerix (CMRX) Shares Plunge After Brincidofovir Fails in Phase III Trial     12/29/2015
Fate Therapeutics (FATE) Discontinues Development of ProHema in Patients Undergoing Cord Blood HCT     12/7/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Rigel Pharmaceuticals, Inc. (RIGL) Experimental Eye Drug R348 Fails Mid-Stage Study     8/14/2014
DOR BioPharma, Inc. (DORB) Receives Guidance From FDA on Proposed Confirmatory Phase 3 Clinical Trial Design of orBec(R) in GI GVHD     11/10/2008
DOR BioPharma, Inc. (DORB) Has Voluntarily Withdrawn European Marketing Authorization Application (MAA) For Orbec(R) For The Treatment Of Gastrointestinal Graft-Versus-Host Disease (GI GVHD)     5/22/2008
Osiris Therapeutics, Inc. (OSIR) (Jobs) Receives FDA Fast Track Status for Prochymal(TM) as First-Line Treatment for Acute GvHD     12/10/2007
FDA Advisory Panel Advises Against DOR BioPharma, Inc. (DORB)'s orBec(R) Approval     5/10/2007
FDA Advisory Committee To Review DOR BioPharma, Inc. (DORB)'s orBec(R) For The Treatment Of GI GVHD     1/31/2007
Pharming Group (PHGUF.PK)'s Lead Drug Receives Orphan Drug Designations From The FDA; Shares Soar     6/14/2006
Osiris Therapeutics, Inc. First To Announce FDA Fast Track Designation For A Stem Cell Product; Decision Seen As A Positive Sign For Both Osiris And The Emerging Stem Cell Industry     1/31/2005

News from Around the Web
Treatment May Limit Graft-Versus-Host Disease, Universitatsklinikum Freiburg Study     8/20/2009
Embryonic Stem Cells Reduce Transplantation Rejection, University of Iowa Study     9/16/2008
Bone Marrow Transplants: Cancer Drug Shows Promise Against Graft Vs. Host Disease in University of Michigan Study     7/17/2008
Immune Molecule that Plays a Powerful Role in Avoiding Organ Rejection Identified in Medical College of Georgia Study     6/20/2008
Mesenchymal Stem Cells Can Suppress Life-Threatening Immune Reaction, Karolinska Institute and Karolinska University Hospital Study     5/14/2008
Uncooked Fish Linked with Liver Cancer in Asia -- Graft-Versus-Host Disease     7/10/2007
Study Shows Rituximab Effective In Treating Chronic Graft-Versus-Host Disease     3/24/2006
New Tissue "Grown Within Minutes"     10/17/2005
Transplant Rejection Averted By Simple Light Exposure In Stanford Animal Study     5/7/2004
Level Of Immune Cells Predict Chances Against Leukemia     3/19/2004
Drugs Limit Deadly Side Effects Of Graft-Versus-Host Disease     3/1/2004

Press Releases
Kalytera Receives IRB Approval For Proposed Phase II Study Evaluating CBD In The Prevention Of Graft Versus Host Disease     9/7/2017
FDA Grants Orphan Drug Status To Cellect (APOP)'s ApoGraft For Acute GvHD And Chronic GvHD     9/5/2017
Kalytera Submits Phase II Study Protocol To Irbs For Cannabidiol In The Prevention Of Graft Versus Host Disease     8/14/2017
Ocugen, Inc. Receives FDA Orphan Drug Designation For OCU300 (Brimonidine Tartrate) For The Treatment Of Ocular Graft Versus Host Disease     8/9/2017
Johnson & Johnson (JNJ)'s Imbruvica Scores Expanded FDA Approval for Chronic Graft vs Host Disease     8/3/2017
Kadmon Announces Supplemental Interim Phase II Data Of KD025 In Chronic Graft-Versus-Host Disease     7/25/2017
Incyte (INCY) Announces First Patient Treated In Phase III Clinical Trial Of Itacitinib For Acute Graft-Versus-Host Disease     7/20/2017
FDA Meeting Provides Clear Path For Cynata U.S. Development Plans     7/5/2017
European Hematology Association: Multicenter Open-Label Phase 2 Study Of Ibrutinib In Chronic Graft Versus Host Disease (cGVHD) After Failure Of Corticosteroids     6/26/2017
Neovii Pharma: Long-Term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis In Hemopoietic Cell Transplantation From Matched Unrelated Donors Strongly Support The Use Of Grafalon (Anti-Human-T-Lymphocyte Immunoglobulin) As Standard Therapy     6/26/2017
Kamada Ltd. (KMDA) Provides Update On Clinical Program For Alpha-1 Antitrypsin IV For Treatment Of Graft-Versus-Host Disease     6/7/2017
CytoDyn (CYDY) Treats First Patient With PRO 140 In Phase II Trial For Graft Versus Host Disease     5/17/2017
Janssen R&D Release: U.S. FDA Accepts For Review The Application Of Ibrutinib (IMBRUVICA) For Chronic Graft-Versus-Host-Disease (Cgvhd) After Failure Of One Or More Lines Of Systemic Therapy     4/4/2017
AbbVie (ABBV) Announces Ibrutinib (IMBRUVICA) Supplemental New Drug Application For Previously Treated Chronic Graft-Versus-Host-Disease (Cgvhd) Accepted For Review By U.S. FDA     4/4/2017
Kamada Ltd. (KMDA) To Host R&D Day Focused On Graft Versus Host Disease (GvHD)     3/3/2017

//-->